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Journal of Parenteral and Enteral Nutrition 37 (1) What is the desired blood glucose goal range in adult hospitalized patients receiving nutrition support?
We recommend a target blood glucose goal range of 140-180 mg/dL (7.8-10 mmol/L).
Strong
How is hypoglycemia defined in adult hospitalized patients receiving nutrition support?
We recommend that hypoglycemia be defined as a blood concentration of <70 mg/dL (<3.9 mmol/L).
Should diabetes-specific enteral formulas be used for adult hospitalized patients with hyperglycemia?
We cannot make a recommendation at this time.
Further research needed in the fields of nutrition and metabolic support in all healthcare settings. These Clinical Guidelines were developed under the guidance of the A.S.P.E.N. Board of Directors. Promotion of safe and effective patient care by nutrition support practitioners is a critical role of the A.S.P.E.N. organization. The A.S.P.E.N. Board of Directors has been publishing Clinical Guidelines since 1986. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] A.S.P.E.N. evaluates in an ongoing process when individual Clinical Guidelines should be updated. These A.S.P.E.N. Clinical Guidelines are based on general conclusions of health professionals who, in developing such guidelines, have balanced potential benefits to be derived from a particular mode of medical therapy against certain risks inherent with such therapy. However, the professional judgment of the attending health professional is the primary component of quality medical care. Because guidelines cannot account for every variation in circumstances, the practitioner must always exercise professional judgment in their application. These Clinical Guidelines are intended to supplement, but not replace, professional training and judgment.
A.S.P.E.N. Clinical Guidelines have adopted concepts of the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) working group. [15] [16] [17] A full description of the methodology has been published. 18 Briefly, specific clinical questions where nutrition support is a relevant mode of therapy are developed and key clinical outcomes are identified. A rigorous search of the published literature is conducted, each included study assessed for research quality, tables of findings developed, the body of evidence for the question evaluated, and a recommendation for clinical practice that is based on both the best available evidence and the risks and benefits to patients developed by consensus. Recommendations are graded as strong when the evidence is strong and/or net benefits outweigh harms. Weak recommendations may be based on weaker evidence and/or important trade-offs to the patient. When limited research is available to answer a question, no recommendation can be made.
Results
For the current Clinical Guideline, inclusion criteria of adult subjects, complication of hyperglycemia, and hospital setting were used. The questions are summarized in Table 1 Recommendation: We recommend a target blood glucose goal range of 140-180 mg/dL (7.8-10 mmol/L).
Grade: Strong
Rationale: Hyperglycemia is associated with increased mortality in hospitalized patients, both in the ICU 19 and the non-ICU setting. 20 No clinical trials have been specifically designed to determine the effect of different blood glucose targets in adult hospitalized patients receiving nutrition support on clinical outcomes.
Earlier studies [21] [22] [23] showed that management of hyperglycemia with an insulin infusion in the ICU was associated with a reduction in mortality, leading a consensus conference to recommend that blood glucose concentrations in hospitalized patients be maintained below 110 mg/dL (6.1 mmol/L). 34 However, more recent large clinical trials failed to show benefit when such an aggressive target was achieved. 25, [27] [28] [29] [30] [31] 35 The largest randomized controlled trial that used primarily enteral nutrition at levels of energy intake that were appropriate actually found a higher mortality in patients treated with intensive treatment compared with those treated to a target blood glucose range of 140-180 mg/dL (7.8-10 mmol/L). 31 The explanation for these disparate results is not entirely clear, but hypoglycemia associated with aggressive treatment in the more recent studies is one likely explanation. It is apparent that mild to moderate hypoglycemia (40-70 mg/dL; 2.2-3.9 mmol/L) is not innocuous but rather is associated with adverse outcomes. No trials have compared a broader target glycemic range with a lower limit, for example, 110-180 mg/dL (6.1-10.0 mmol/L), to intensive treatment. Because of these findings, we recommend that the target blood glucose concentration in the critically ill adult should be 140-180 mg/dL (7.8-10 mmol/L). No randomized controlled trials have been conducted in non-ICU patients. This recommendation is consistent with those of the American Association of Clinical Endocrinologists, the American Diabetes Association, 36 and the Endocrine Society. 37 Question 2. How is hypoglycemia defined in adult hospitalized patients receiving nutrition support (Tables 4 and 5)?
Recommendation: We recommend that hypoglycemia be defined as a blood glucose concentration of <70 mg/dL (<3.9 mmol/L).
Grade: Strong Rationale: Hypoglycemia is associated with adverse outcomes in hospitalized patients. 25, 38, 39, [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] Hypoglycemia could be partly responsible for the adverse effects noted with intensive insulin therapy, including mortality. 25 A large retrospective analysis of hypoglycemia in ICUs showed a stepwise and significant increase in mortality with increasingly severe hypoglycemia. 38 This recommendation carries a strong recommendation grade based on our assessment of the significant risk to the patient of hypoglycemia in the context of tight glucose control.
Symptoms of hypoglycemia can be missed in hospitalized patients who are sedated or ventilated, or with impaired sensorium. The American Diabetes Association Workgroup on Hypoglycemia and the American Association of Clinical Endocrinologists and American Diabetes Association Consensus Statement on Inpatient Glycemic Control define hypoglycemia as any blood glucose <70 mg/dL (<3.9 mmol/L). 36 This value is the accepted definition in ambulatory patients and is a level at which counterregulatory hormone release (including sympathoadrenal activation) occurs. It is reasonable to apply the definition of hypoglycemia in ambulatory patients to hospitalized patients. Antecedent hypoglycemia of this level can reduce the secretion of counterregulatory hormones resulting in impaired responsiveness to subsequent hypoglycemia. [55] [56] [57] While some studies have defined hypoglycemia in critically ill patients as <40 mg/ dL (<2.2 mmol/L), that threshold is lower than the level at which cognitive impairment can occur and is therefore not safe. In addition, a variety of point-of-care testing methods for blood glucose are used in hospitalized patients. The accuracy and precision of blood glucose monitoring devices is relatively poor, especially at low glucose concentrations. 14, 58 Using a blood glucose threshold of 70 mg/dL (3.9 mmol/L) instead of a lower value offers the additional benefit of a safety buffer to accommodate such testing errors. Regardless of the definition threshold of hypoglycemia, patients with symptoms of hypoglycemia at a higher level than 70 mg/dL (3.9 mmol/L) may require treatment for symptoms of hypoglycemia.
Question 3. Should diabetes-specific enteral formulas be used for hospitalized patients with hyperglycemia (Tables 6  and 7) ?
Recommendation: We cannot make a recommendation at this time.
Grade: Further research needed Rationale: The availability of enteral formulas with lower carbohydrate and higher monounsaturated fat content (compared with standard formulas commonly used in clinical settings) and with or without added fiber has prompted studies examining the effects on glycemic control. Additionally, most trials are short-term or single-meal studies, use oral nutrition supplements, or were conducted in long-term care facilities, rehabilitation, or other outpatient settings, limiting their application to hospitalized patients requiring enteral nutrition.
The trials that evaluated disease-specific formulas in patients requiring long-term nutrition support used glycemic or lipid control as their primary outcomes, as they were not sufficiently powered to detect differences in morbidity and/or mortality. 59, 60 The impact on glycemic and lipid control was inconclusive. Additional research is required. 22, 23 no different in 5
RCTs, 25, [27] [28] [29] [30] and worse in the largest RCT 31 ; 5 retrospective reviews suggest harm with PN-associated hyperglycemia 2, 24, 26, 32, 33 Moderate Strong PN, parenteral nutrition; RCT, randomized controlled trial. 
